Sabra Healthcare REIT, Inc.
SBRA
$18.46
+4.47%
Sabra Healthcare REIT, Inc. is a real estate investment trust that owns and invests in healthcare real estate, primarily nursing facilities, assisted living centers, and mental health facilities, generating all its revenue in the United States. The company operates as a specialized REIT, focusing on a critical but often challenging segment of the real estate market tied to the aging population and healthcare needs. The current investor narrative centers on the company's recovery from pandemic-era pressures and its ability to navigate a complex operating environment characterized by high interest rates and labor costs, with recent financial results showing improved revenue growth and profitability, sparking debate about the sustainability of its margin expansion and dividend coverage.…
SBRA
Sabra Healthcare REIT, Inc.
$18.46
Investment Opinion: Should I buy SBRA Today?
Rating: Hold. The core thesis is that SBRA presents a conflicted picture of improving fundamentals against severe technical damage and a rich valuation, resulting in a balanced risk/reward that favors waiting for clearer confirmation of a sustained turnaround.
Supporting this view, the stock's 29.37x trailing P/E is elevated for a REIT, especially one with a 5.51% ROE. While Q4 revenue growth of 16.21% is impressive, earnings remain volatile and diluted. The stock trades just 4.0% above its 52-week low, suggesting much bad news is priced in, yet the lack of a clear analyst consensus price target and the -17.9% one-month relative strength indicate no near-term catalyst for a rebound. Strong TTM FCF of $348.6M and a manageable 0.90 debt-to-equity ratio provide a fundamental floor.
The thesis would upgrade to Buy if the stock convincingly holds the $17.17 support and the forward P/E of 23.77x compresses further toward 20x on sustained quarterly revenue growth above 10%. It would downgrade to Sell if the 52-week low is breached on high volume or if QoQ revenue growth turns negative. Currently, the stock is fairly valued to slightly overvalued relative to its own volatile history and the challenging sector backdrop, pricing in a recovery that has yet to be fully realized in consistent earnings power.
Sign up to view all
SBRA 12-Month Price Forecast
The outlook for SBRA is one of high uncertainty, balancing clear operational improvement against powerful technical and valuation headwinds. The base case of sideways consolidation is most probable (55%), as the market requires more than one quarter of strong growth to rebuild confidence. The stock's low beta (0.65) and high short interest could fuel a sharp rally on any positive news, but the primary path is likely one of time-consuming base-building. The stance would upgrade to bullish on a confirmed hold of the $17.17 support coupled with a second consecutive quarter of >10% revenue growth. It would turn bearish on a break below $17 with high volume, signaling the downtrend's resumption.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Sabra Healthcare REIT, Inc.'s 12-month outlook, with a consensus price target around $24.00 and implied upside of +30.0% versus the current price.
Average Target
$24.00
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$15 - $24
Analyst target range
Analyst coverage for SBRA appears limited, with the provided data indicating only one analyst providing revenue estimates, and a series of recent institutional rating actions from firms like Wells Fargo, Citigroup, and UBS. The consensus sentiment from these recent ratings is mixed but leans neutral-to-positive, with actions including 'Overweight' (Wells Fargo), 'Buy' (Citigroup), and 'Market Outperform' (Citizens) balanced against 'Hold' (Truist), 'Neutral' (UBS), and 'Sector Perform' (Scotiabank) ratings. The lack of a clear consensus price target in the provided data suggests limited or fragmented analyst coverage, which is common for smaller-cap REITs and can lead to higher volatility and less efficient price discovery. The range of analyst actions, with no outright sells but several neutral holds, indicates a cautious optimism where analysts recognize the company's improving fundamentals and niche but see headwinds from macro factors like interest rates. The recent flurry of rating reaffirmations in Q1 2026, without major changes, suggests analysts are in a 'wait-and-see' mode, monitoring the company's ability to sustain its operational recovery before becoming more bullish.
Bulls vs Bears: SBRA Investment Factors
The evidence currently favors the bear case, as the severe technical breakdown and valuation premium outweigh the improving fundamentals. The most important tension in the investment debate is whether the strong Q4 revenue growth (16.21% YoY) marks the beginning of a sustainable operational recovery that can justify the stock's high P/E multiple (29.37x), or if the recent price collapse signals a fundamental reassessment of the company's prospects in a challenging macro environment for REITs. The resolution of this growth-versus-valuation disconnect will determine the stock's direction.
Bullish
- Strong Revenue Growth Acceleration: Q4 2025 revenue grew 16.21% YoY to $211.9M, a significant acceleration from prior quarters. This sequential growth from $190.0M in Q3 suggests a robust recovery in the core healthcare real estate portfolio.
- Robust Profitability and Cash Flow: The company maintains healthy margins with a Q4 gross margin of 62.05% and operating margin of 30.48%. Strong TTM free cash flow of $348.6M provides ample coverage for dividends and operations.
- Deeply Oversold Technical Condition: The stock is trading at $17.67, just 4.0% above its 52-week low of $17.17, after a severe 13.30% one-month decline. This oversold condition, coupled with a low beta of 0.65, suggests limited fundamental downside and a potential technical rebound.
- Manageable Leverage for a REIT: A debt-to-equity ratio of 0.90 is moderate for a capital-intensive REIT. This provides financial flexibility and reduces refinancing risk relative to more highly leveraged peers.
Bearish
- Severe Price Momentum Breakdown: The stock has underperformed the S&P 500 by -17.9% over the past month and -26.1% over three months. This accelerating downtrend, culminating near 52-week lows, indicates persistent and powerful selling pressure.
- Elevated Valuation Despite Weakness: A trailing P/E of 29.37x and forward P/E of 23.77x are high for a REIT, especially one with a modest 5.51% ROE. This premium valuation leaves little room for error and is vulnerable to compression if growth falters.
- Volatile and Depressed Earnings: Quarterly net income swung from $65.5M in Q2 2025 to $22.5M in Q3 2025, highlighting operational lumpiness. The current diluted EPS of $0.034 is extremely low, raising questions about the quality and sustainability of profits.
- Weak Liquidity and High Payout: A current ratio of 0.56 indicates limited short-term liquidity, which is a concern in a high-rate environment. A payout ratio of 186% signals the dividend is not fully covered by earnings, posing a risk to the income stream.
SBRA Technical Analysis
The stock is in a pronounced downtrend, having lost 13.30% over the past month and 13.47% over the past three months, starkly underperforming the S&P 500, which gained 4.6% and 12.6% over the same periods, respectively. Currently trading at $17.67, the price is near the bottom of its 52-week range ($17.17 - $21.28), sitting at just 4.0% above its 52-week low, which signals significant technical weakness and potential capitulation selling. This positioning near multi-month lows suggests the stock is deeply oversold, presenting a potential value opportunity but also indicating persistent negative momentum that could lead to a test of the 52-week low. Recent momentum is decisively negative and accelerating, with the 1-month decline of 13.30% far exceeding the modest 0.23% 1-year gain, indicating a severe short-term breakdown that diverges from its flat longer-term performance. The stock's beta of 0.654 indicates it is approximately 35% less volatile than the broader market, but this defensive characteristic has not shielded it from the recent aggressive sell-off, as evidenced by its relative strength of -17.9% against the SPY over the past month. Key technical support is firmly established at the 52-week low of $17.17, with a breach below this level potentially triggering further downside, while initial resistance lies near the recent breakdown level around $19 and more significant resistance at the 52-week high of $21.28. The stock's low beta suggests it should exhibit lower volatility, yet the recent sharp drawdown of -16.65% from its recent high highlights elevated idiosyncratic risk, making a decisive break below the $17.17 support a critical watchpoint for confirming a continuation of the bearish trend.
Beta
0.63
0.63x market volatility
Max Drawdown
-16.6%
Largest decline past year
52-Week Range
$17-$21
Price range past year
Annual Return
+3.9%
Cumulative gain past year
| Period | SBRA Return | S&P 500 |
|---|---|---|
| 1m | -10.0% | -0.0% |
| 3m | -9.6% | +8.7% |
| 6m | -4.3% | +8.0% |
| 1y | +3.9% | +23.1% |
| ytd | -3.6% | +8.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SBRA Fundamental Analysis
Revenue growth has shown a positive trajectory, with Q4 2025 revenue of $211.9 million representing a 16.21% year-over-year increase, a significant acceleration from the low-single-digit growth seen in prior quarters. Sequentially, revenue grew from $190.0 million in Q3 2025, indicating strong quarterly momentum. This growth is primarily driven by the core healthcare real estate portfolio, as segment data is limited, suggesting the recovery is broad-based across its property types. The company is profitable, reporting Q4 2025 net income of $27.2 million and a trailing twelve-month net margin of 20.09%. Gross margin for the quarter was a healthy 62.05%, and the operating margin was 30.48%, indicating efficient property-level operations. However, profitability has been volatile on a quarterly basis, with net income swinging from $65.5 million in Q2 2025 to $22.5 million in Q3 2025, reflecting the lumpy nature of real estate operations and potential one-time items. The balance sheet and cash flow picture is mixed; the company generated substantial free cash flow of $348.6 million on a TTM basis, providing strong coverage for its operations and dividends. The debt-to-equity ratio of 0.90 is manageable for a REIT, indicating a moderate leverage level. However, the current ratio of 0.56 points to relatively low liquidity, which is typical for REITs that hold assets, not cash, but warrants monitoring in a higher interest rate environment. Return on equity is a modest 5.51%, reflecting the capital-intensive nature of the business.
Quarterly Revenue
$211902000.0B
2025-12
Revenue YoY Growth
+0.16%
YoY Comparison
Gross Margin
+0.62%
Latest Quarter
Free Cash Flow
$348613000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SBRA Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E ratio is elevated at 29.37x, while the forward P/E is 23.77x, indicating the market expects earnings growth to improve, which aligns with the recent quarterly revenue acceleration. Compared to its own historical range, the current trailing P/E of 29.37x is above the multi-quarter average seen in the historical data (which has fluctuated between negative values and the 40s), suggesting the market is pricing in a recovery narrative despite the recent price decline. The stock trades at a premium to typical REIT valuations based on its Price-to-Funds from Operations (P/FFO) proxy; the Price-to-Cash Flow ratio of 13.11x and EV/EBITDA of 15.43x are more standard for the sector, but the high P/E indicates GAAP earnings are still depressed relative to the stock price. The historical P/E data shows significant volatility, with values ranging from negative figures during loss-making periods to over 40x, placing the current 29.37x near the upper end of its profitable-cycle range, implying optimism is already embedded. The stock's Price-to-Sales ratio of 5.90x and Price-to-Book of 1.62x are also key for asset-heavy REITs, with the P/B ratio suggesting the market values the company slightly above its accounting book value, which is reasonable for a stable cash-flowing entity.
PE
29.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -70x~80x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: SBRA's financials reveal significant earnings volatility, with quarterly net income swinging from $65.5M to $22.5M within recent quarters, complicating predictability. The dividend appears strained with a payout ratio of 186%, indicating it is funded from sources other than current earnings, and a low current ratio of 0.56 highlights limited liquidity to navigate unexpected expenses or debt maturities. While TTM free cash flow of $348.6M is strong, the reliance on this metric to cover the dividend introduces risk if property-level cash flows weaken.
Market & Competitive Risks: The stock trades at a significant premium to typical REIT valuations, with a trailing P/E of 29.37x, making it highly susceptible to valuation compression if growth expectations are not met. Its beta of 0.65 suggests it is less volatile than the market, yet it has dramatically underperformed the S&P 500 by nearly 27% over the past year, indicating severe sector-specific and idiosyncratic headwinds, likely related to high interest rates pressuring REIT valuations and operational cost inflation in healthcare. The mixed analyst sentiment, with several 'Hold' or 'Neutral' ratings, reflects skepticism about near-term catalysts to reverse the negative momentum.
Worst-Case Scenario: The worst-case scenario involves a breach of the key $17.17 technical support level, triggering further algorithmic and momentum selling. This could be catalyzed by a disappointing earnings report showing a reversion to low-single-digit revenue growth or margin contraction, leading analysts to downgrade the stock. Combined with a persistent high-interest-rate environment compressing REIT multiples, this could see the stock re-test levels not seen since the pandemic, with a realistic downside of -20% to -25% from the current price, pushing it toward the $13-$14 range based on a further de-rating of its P/E multiple toward 20x.
FAQ
The key risks are: 1) Valuation Compression: The high P/E of 29.37x could contract sharply if growth slows. 2) Dividend Sustainability: A payout ratio of 186% indicates the dividend is not fully covered by earnings, risking a cut. 3) Operational Volatility: Quarterly net income swings (e.g., $65.5M to $22.5M) make forecasting difficult. 4) Macro/Sector Pressure: High interest rates and labor costs continue to pressure healthcare REIT profitability and valuations, as evidenced by the stock's severe underperformance versus the market.
The 12-month forecast presents three scenarios. The Base Case (55% probability) sees the stock trading between $18.50 and $20.50 as growth moderates and the stock consolidates. The Bull Case (25% probability), requiring sustained high growth and a Fed pivot, targets $21.00 to $23.00. The Bear Case (20% probability), triggered by broken support and stalled growth, sees a drop to $15.00-$17.17. The base case is most likely, implying limited near-term upside from the current $17.67 price until earnings visibility improves.
SBRA appears overvalued based on earnings but may be fairly valued on cash flow. Its trailing P/E of 29.37x is high for a REIT, especially one with volatile quarterly income and a 5.51% ROE. However, its Price-to-Cash Flow of 13.11x and EV/EBITDA of 15.43x are more in line with sector averages. The market is pricing in a significant recovery in earnings power (forward P/E of 23.77x), making the stock vulnerable if that growth does not materialize consistently. Relative to its own history and current challenges, it is fairly valued to slightly overvalued.
SBRA is a speculative buy only for investors with a high risk tolerance and a long-term horizon. The 6.33% dividend yield is attractive, and the stock is deeply oversold, trading just 4.0% above its 52-week low. However, the elevated 29.37x P/E ratio and severe recent underperformance (-13.30% in one month) present significant risks. It could be a good buy for contrarian investors betting on a operational turnaround, but it requires patience and a willingness to average down if the $17.17 support breaks.
SBRA is unsuitable for short-term trading due to its low beta (0.65) and lack of near-term catalysts amidst a severe downtrend. It is better suited for long-term, income-oriented investors willing to hold for 3-5 years to realize the potential demographic-driven recovery in healthcare real estate. The high dividend yield (6.33%) supports a total return approach, but investors must be prepared for volatility and possess the patience to wait for operational improvements to translate into consistent share price appreciation. A minimum holding period of 18-24 months is recommended to assess the turnaround thesis.